HK Stock Market Move | Ximei Resources (09936) rose more than 14% to a new high. Strategic metals may face revaluation. The company is a leading producer of Chinese tantalum-niobium metallurgical products.
Rare Earth Resources (09936) surged over 14% to hit a new high. As of the time of writing, it was up 10.3% and trading at 15.42 Hong Kong dollars, with a trading volume of 13.6647 million Hong Kong dollars.
XIMEI RESOURCES(09936) rises more than 14% to hit a new high. As of the time of writing, it is up 10.3% at 15.42 Hong Kong dollars, with a trading volume of 13.66 million Hong Kong dollars.
In terms of news, the United States is planning to set reference prices for global critical mineral trade. A research report released by Global Wealth indicates that niobium and tantalum are important strategic resources with irreplaceable positions in the defense and military industry. In recent years, with the outbreak of domestic demand, the importance of controlling niobium and tantalum resources independently has become increasingly prominent. With the country's increasing attention and continuous investment in the rare metal industry, the domestic niobium and tantalum industry has entered a golden period of rapid development.
Hui Li Securities released a research report stating that XIMEI RESOURCES is a core producer of tantalum and niobium metallurgical products in China. Ganfeng Lithium Group currently holds a 15.79% stake in XIMEI RESOURCES, making them the second largest shareholder. Ganfeng Lithium Group, as a global leader in the lithium industry, has long focused on the new energy metal industry chain. Tantalum and niobium are key materials in high-end fields such as semiconductors, aerospace, and aviation, and belong to the strategic metal category along with lithium resources. Through its stake in XIMEI RESOURCES, Ganfeng Lithium Group aims to expand its strategic metal portfolio and improve its industry chain synergy in the high-end materials sector.
Related Articles

HK Stock Market Move | INNOCARE (09969) rose by more than 4% in the final trading session, completion of patient enrollment in Phase III clinical trial of BCL2 inhibitor combined with Apatinib.

Citibank: The budget confirms that the scope of Hong Kong's economic recovery will expand, with fiscal reserves expected to remain stable.

Caitong: Maintains "Buy" rating on TRIP.COM-S (09961) Performance exceeds expectations and internationalization drive continues.
HK Stock Market Move | INNOCARE (09969) rose by more than 4% in the final trading session, completion of patient enrollment in Phase III clinical trial of BCL2 inhibitor combined with Apatinib.

Citibank: The budget confirms that the scope of Hong Kong's economic recovery will expand, with fiscal reserves expected to remain stable.

Caitong: Maintains "Buy" rating on TRIP.COM-S (09961) Performance exceeds expectations and internationalization drive continues.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


